The administration of an anti-integrin β1 antibody and FAK inhibitor effectively inactivated YAP and its downstream PI3K/Akt signaling, resulting in decreased cancer stemness markers CD133, ALDH-1, and LGR-5 [35]. Here, ALDH1A1 is linked to cancer.